Emerging infectious diseases · 2023

Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India.

СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Muthu Valliappan, Agarwal Ritesh, Rudramurthy Shivaprakash Mandya, Thangaraju Deepak, Shevkani Manoj Radhakishan, Patel Atul K, Shastri Prakash Srinivas, Tayade Ashwini, Bhandari Sudhir, Gella Vishwanath, Savio Jayanthi, Madan Surabhi, Hallur Vinay Kumar, Maturu Venkata Nagarjuna, Srinivasan Arjun, Sethuraman Nandini, Sibia Raminder Pal Singh, Pujari Sanjay, Mehta Ravindra, Singhal Tanu, Saxena Puneet, Gupta Varsha, Nagvekar Vasant, Prayag Parikshit, Patel Dharmesh, Xess Immaculata, Savaj Pratik, Panda Naresh, Rajagopal Gayathri Devi, Parwani Riya Sandeep, Patel Kamlesh, Deshmukh Anuradha, Vyas Aruna, Sistla Srinivas Kishore, Padaki Priyadarshini A, Ramar Dharshni, Sarkar Saurav, Rachagulla Bharani, Vallandaramam Pattabhiraman, Premachandran Krishna Prabha, Pawar Sunil, Gugale Piyush, Hosamani Pradeep, Dutt Sunil Narayan, Nair Satish, Kalpakkam Hariprasad, Badhwar Sanjiv, Kompella Kiran Kumar, Singla Nidhi, Navlakhe Milind, Prayag Amrita, Singh Gagandeep, Dhakecha Poorvesh, Chakrabarti Arunaloke

Аннотация

We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.

Предметные рубрики MeSH

Humans Mucormycosis COVID-19 Case-Control Studies Mucorales India Multicenter Studies as Topic

Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH